Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Grace Therapeutics, Inc GRCE

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.


NDAQ:GRCE - Post by User

Bullboard Posts
Comment by EternalPonzion Jan 14, 2020 11:26am
184 Views
Post# 30551033

RE:RE:Company response

RE:RE:Company response
I would have liked them to publish results minus those 5 sites. reaction still would have been negative but not to the degree we saw yesterday. Stock will ever so slowly trade up over the next few weeks. After some profit taking, for those who bought at extreme lows, we will reach a stand off between sellers unwilling to sell for 'cheap' (believing next set of results and explanations for erroneous results will be positive) and buyers unwilling to buy for fear of getting burned (will relent due to fear of missing out). Expect $1.25 - $1.50US ($1.60 - $1.90CDN) before next results PR released. If results good and there is a way forward probably back to about equilibrium level of about $3.00US - after day traders have taken profits. Then we move to next phase of development and perhaps renewed interest and new price targets. If results not so good then things will be grim.
Bullboard Posts